| A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (NCT06176352) | Hoffmann-La Roche | 2024-03-06 |
| A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants (NCT06189508) | Hoffmann-La Roche | 2024-02-14 |
| A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration (NCT05126966) | Hoffmann-La Roche | 2023-12-29 |
| A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (NCT05835986) | Hoffmann-La Roche | 2023-12-18 |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma (NCT06055075) | Hoffmann-La Roche | 2023-12-12 |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) (NCT06065748) | Hoffmann-La Roche | 2023-12-11 |
| A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers (NCT06496568) | Hoffmann-La Roche | 2023-12-11 |
| A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (NCT05908786) | Hoffmann-La Roche | 2023-12-05 |
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (NCT04760288) | Hoffmann-La Roche | 2023-11-30 |
| A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) (NCT06128564) | Hoffmann-La Roche | 2023-11-29 |
| A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts (NCT06094010) | Hoffmann-La Roche | 2023-11-22 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease (NCT06106828) | Hoffmann-La Roche | 2023-11-15 |
| A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (NCT05583617) | Hoffmann-La Roche | 2023-11-14 |
| Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease (NCT05987423) | Hoffmann-La Roche | 2023-10-26 |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (NCT06084936) | Hoffmann-La Roche | 2023-10-22 |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (NCT06047080) | Hoffmann-La Roche | 2023-09-18 |
| A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis (NCT05208840) | Hoffmann-La Roche | 2023-09-15 |
| A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) (NCT05904886) | Hoffmann-La Roche | 2023-09-14 |
| A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer (NCT05846594) | Hoffmann-La Roche | 2023-09-14 |
| A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer (NCT05945927) | Hoffmann-La Roche | 2023-09-13 |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (NCT05894239) | Hoffmann-La Roche | 2023-09-08 |
| A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma (NCT05954910) | Hoffmann-La Roche | 2023-08-25 |
| A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery (NCT05872763) | Hoffmann-La Roche | 2023-08-11 |
| A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (NCT05797610) | Hoffmann-La Roche | 2023-08-08 |
| A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (NCT05630066) | Hoffmann-La Roche | 2023-07-27 |
| Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease (NCT05910528) | Hoffmann-La Roche | 2023-07-24 |
| A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (NCT05852691) | Hoffmann-La Roche | 2023-07-18 |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) (NCT05878769) | Hoffmann-La Roche | 2023-06-28 |
| A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (NCT05634499) | Hoffmann-La Roche | 2023-06-27 |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (NCT05789082) | Hoffmann-La Roche | 2023-06-20 |
| Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (NCT05769959) | Hoffmann-La Roche | 2023-06-15 |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (NCT05646862) | Hoffmann-La Roche | 2023-06-07 |
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study (NCT05862285) | Hoffmann-La Roche | 2023-06-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (NCT05661578) | Hoffmann-La Roche | 2023-05-04 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection (NCT05763576) | Hoffmann-La Roche | 2023-04-28 |
| A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (NCT05805501) | Hoffmann-La Roche | 2023-04-21 |
| A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) (NCT05459129) | Hoffmann-La Roche | 2023-04-12 |
| A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome (NCT05627557) | Hoffmann-La Roche | 2023-03-29 |
| Vamikibart in Participants With Uveitic Macular Edema (NCT05642325) | Hoffmann-La Roche | 2023-03-23 |
| A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (NCT05775289) | Hoffmann-La Roche | 2023-03-15 |
| Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice (NCT05694013) | Hoffmann-La Roche | 2023-02-27 |
| A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy (NCT05548556) | Hoffmann-La Roche | 2023-02-07 |
| GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease (NCT05686551) | Hoffmann-La Roche | 2023-02-03 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas (NCT05619744) | Hoffmann-La Roche | 2023-01-23 |
| A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema (NCT05642312) | Hoffmann-La Roche | 2023-01-09 |
| A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (NCT05595642) | Hoffmann-La Roche | 2022-12-29 |
| A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome (NCT05307679) | Hoffmann-La Roche | 2022-12-16 |
| A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections (NCT05614895) | Hoffmann-La Roche | 2022-12-03 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) (NCT05494619) | Hoffmann-La Roche | 2022-11-30 |
| A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (NCT05476926) | Hoffmann-La Roche | 2022-11-21 |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (NCT05533775) | Hoffmann-La Roche | 2022-11-16 |
| A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma (NCT05364424) | Hoffmann-La Roche | 2022-11-04 |
| A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (NCT05170204) | Hoffmann-La Roche | 2022-11-01 |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (NCT05169515) | Hoffmann-La Roche | 2022-10-26 |
| A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe (NCT05569148) | Hoffmann-La Roche | 2022-10-17 |
| A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (NCT05535244) | Hoffmann-La Roche | 2022-10-17 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis (NCT05503264) | Hoffmann-La Roche | 2022-09-27 |
| A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease. (NCT05924243) | Hoffmann-La Roche | 2022-09-22 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (NCT05271409) | Hoffmann-La Roche | 2022-08-30 |
| A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (NCT05419388) | Hoffmann-La Roche | 2022-08-15 |
| A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (NCT05269667) | Hoffmann-La Roche | 2022-08-02 |
| Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD) (NCT05401565) | Hoffmann-La Roche | 2022-08-02 |
| Screening Study for Participants With Malignant Tumors (NCT05419375) | Hoffmann-La Roche | 2022-07-22 |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) (NCT05296798) | Hoffmann-La Roche | 2022-07-18 |
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (NCT05415215) | Hoffmann-La Roche | 2022-07-05 |
| The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan (NCT03912350) | Hoffmann-La Roche | 2022-06-26 |
| Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema (NCT05399550) | Hoffmann-La Roche | 2022-06-22 |
| A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (NCT05181618) | Hoffmann-La Roche | 2022-06-20 |
| A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NCT05047250) | Hoffmann-La Roche | 2022-06-14 |
| A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19 (NCT05164133) | Hoffmann-La Roche | 2022-06-10 |
| A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy (NCT05115110) | Hoffmann-La Roche | 2022-06-02 |
| A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System (NCT05275010) | Hoffmann-La Roche | 2022-05-30 |
| A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) (NCT05123703) | Hoffmann-La Roche | 2022-05-19 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (NCT05039619) | Hoffmann-La Roche | 2022-05-12 |
| An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma (NCT05315713) | Hoffmann-La Roche | 2022-05-10 |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (NCT05269004) | Hoffmann-La Roche | 2022-05-03 |
| A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (NCT05232825) | Hoffmann-La Roche | 2022-05-03 |
| A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NCT05171647) | Hoffmann-La Roche | 2022-04-25 |
| A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (NCT05256134) | Hoffmann-La Roche | 2022-04-19 |
| A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma (NCT05187624) | Hoffmann-La Roche | 2022-04-05 |
| A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer (NCT05171777) | Hoffmann-La Roche | 2022-04-04 |
| A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD). (NCT04912869) | Hoffmann-La Roche | 2022-03-26 |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma (NCT04980222) | Hoffmann-La Roche | 2022-03-22 |
| A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer (NCT05009069) | Hoffmann-La Roche | 2022-03-18 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) (NCT05075824) | Hoffmann-La Roche | 2022-03-09 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT05091424) | Hoffmann-La Roche | 2022-03-07 |
| A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) (NCT05119569) | Hoffmann-La Roche | 2022-03-01 |
| An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (NCT05251948) | Hoffmann-La Roche | 2022-03-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NCT05219513) | Hoffmann-La Roche | 2022-02-18 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (NCT05116202) | Hoffmann-La Roche | 2022-02-02 |
| A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema (NCT05151731) | Hoffmann-La Roche | 2021-12-31 |
| A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema (NCT05151744) | Hoffmann-La Roche | 2021-12-17 |
| An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) (NCT05112965) | Hoffmann-La Roche | 2021-12-01 |
| A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (NCT05091567) | Hoffmann-La Roche | 2021-11-18 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (NCT04958265) | Hoffmann-La Roche | 2021-11-17 |
| A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome (NCT06734117) | Hoffmann-La Roche | 2021-11-15 |
| A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (NCT04712097) | Hoffmann-La Roche | 2021-10-27 |
| A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus (NCT04963296) | Hoffmann-La Roche | 2021-10-26 |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (NCT04929223) | Hoffmann-La Roche | 2021-10-22 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (NCT04861259) | Hoffmann-La Roche | 2021-10-22 |